Description
LinATAB M 2.5/1000 ER is an extended-release combination medication that contains linagliptin and metformin, designed for the management of type 2 diabetes mellitus. Linagliptin, a DPP-4 inhibitor, enhances insulin secretion and lowers glucagon levels, while metformin improves insulin sensitivity and decreases hepatic glucose production. The extended-release formulation allows for a gradual release of the active ingredients, providing sustained blood sugar control throughout the day. The 2.5/1000 mg dosage indicates the specific strengths of linagliptin and metformin, enabling tailored treatment to meet individual patient needs. LinATAB M is typically prescribed as part of a comprehensive diabetes management plan that includes dietary changes and physical activity. Patients should follow their healthcare provider's instructions for optimal effectiveness and to minimize the risk of side effects.
.jpg)
.jpeg)
 100 IU 3 ML.webp)
.jpeg)
.jpg)
.jpeg)
.jpg)
.jpg)
.jpg)
.webp)
 400MG.jpg)
.jpeg)
.jpg)
.jpg)
.jpg)
.webp)
.webp)
.png)
Change Language